Nuvectis Pharma Inc
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| – | -39,700.0% | – | – | – | – | |
| – | – | -9.8% | +175.6% | +3.3% | +24.2% | |
| – | +0.0% | -9.8% | – | – | – | |
| – | +14,840.0% | +155.6% | -58.1% | +18.4% | +132.2% | |
| – | – | – | – | – | – | |
| – | – | – | – | – | – | |
| – | +0.0% | +82.4% | -45.7% | -22.8% | +149.8% | |
| – | +23,825.0% | +148.2% | -106.1% | – | – | |
| – | -39,700.0% | – | – | – | – |
Data as of: September 22, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.